The chairs of the adult clinical trials groups that make up the NCI National Clinical Trials Network said in a letter that recent budget cuts have triggered a “crisis” in clinical research.
The FDA Molecular and Clinical Genetics Panel voted 10-0 to recommend approval of Cologuard—a noninvasive, multitarget stool DNA screening test for colorectal cancer.
The Centers for Medicare and Medicaid Services is facing the formidable challenge of deciding what kinds of patients should be screened for lung cancer.
NCI is moving toward adopting a formula that will fundamentally restructure the manner in which cancer centers are funded.
NIH has launched a systematic examination of its intramural program, which accounts for 11.1 percent of its $30 billion budget.
Two years ago, NCI officials made a promise to increase the budget of the cooperative groups program by $25.6 million.
NCI has launched a pilot study to assess whether assigning cancer patients treatment based on the genetic characteristics of their disease can improve outcomes for patients with advanced metastatic solid tumors.
A meeting of the FDA Oncologic Drugs Advisory Committee has become a rare occurrence.
You might think of this as an event isolated to Columbus or central Ohio:
Congressional appropriators instructed NIH to cut spending on communications activities and coordinate the broad range of activities that fall under the category of public relations.
